Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Metastatic malignant melanoma is a chemotherapy-refractory cancer.
• Previous research on P-glycoprotein (P-gp) and multidrug resistance (MDR) in melanoma has yielded conflicting results.
• Clarifying the role of P-gp in melanoma is crucial for developing effective treatment strategies.

Purpose of the Study:

• To investigate the presence and functionality of P-glycoprotein (P-gp) in human malignant melanoma cell lines.
• To compare different methods for detecting classical multidrug resistance (cMDR)-associated P-gp.
• To assess the impact of P-gp expression on drug accumulation and cytotoxicity in melanoma.

Main Methods:

• Established 33 human malignant melanoma cell lines from primary and metastatic lesions.
• Utilized immunocytochemistry, P-gp radioimmunometric assay, RT-PCR for MDR-1 mRNA, and slot-blot analysis for P-gp detection.
• Performed functional assays using daunomycin (DM) as a substrate and verapamil (VP) as a cMDR modifier.

Main Results:

• P-gp expression detected by immunocytochemistry in 33% of cell lines, correlating with radioimmunometric assay results.
• MDR-1 mRNA detected by RT-PCR in 76% of cell lines, indicating higher sensitivity than slot-blot analysis.
• Functional assays showed no direct correlation between P-gp levels and drug resistance, but verapamil enhanced drug effects in high P-gp expressing cells.

Conclusions:

• Classical multidrug resistance (cMDR) mediated by P-glycoprotein (P-gp) is not the primary resistance mechanism in malignant melanoma.
• P-gp expression may function as a complementary protective mechanism against cytotoxic agents in melanoma.
• Further research is needed to fully elucidate the complex mechanisms of chemotherapy resistance in malignant melanoma.